News headlines about Cellular Dynamics International (NASDAQ:ICEL) have been trending positive this week, Accern reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellular Dynamics International earned a news impact score of 0.30 on Accern’s scale. Accern also gave news headlines about the company an impact score of 43.5646126812032 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of Cellular Dynamics International (ICEL) opened at 16 on Friday. Cellular Dynamics International has a 1-year low of $5.00 and a 1-year high of $17.00. The firm’s 50-day moving average is $14.00 and its 200-day moving average is $8.00.

TRADEMARK VIOLATION WARNING: This article was published by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at

About Cellular Dynamics International

Cellular Dynamics International, Inc develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics.

Receive News & Ratings for Cellular Dynamics International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Dynamics International Inc and related companies with's FREE daily email newsletter.